Literature DB >> 32508368

Cannabis Use and its Association with Psychological Disorders.

Ivan Urits1, Kyle Gress1, Karina Charipova1, Nathan Li1, Amnon A Berger1, Elyse M Cornett1, Jamal Hasoon1, Hisham Kassem1, Alan D Kaye1, Omar Viswanath1.   

Abstract

Purpose of Review: This is a comprehensive review of the association between cannabis use and psychological disorders. It reviews the latest and seminal evidence that is available and attempts to conclude the strength of such association. Recent Findings: Cannabis is a flowering plant with psychoactive properties, attributed to cannabinoids that naturally occur within the plant. These act through the CB1 and CB2 receptors to inhibit GABA and glutamate release, as well through other forms of neuromodulation through the modulation of the endocannabinoid system (eCBs); a system that is otherwise involved in different pathways, including reward, memory, learning, and pain. Recent societal changes have increased the use of both medical and recreational cannabis. Patients with mental illness are considered more vulnerable and are prone to reward-seeking behavior. Cannabis use disorder (CUD) has been shown to have an increased prevalence in individuals with mental illness, creating an explosive cocktail. Approximately 1 in 4 patients with schizophrenia are also diagnosed with CUD. Cannabis use is associated with 2-4 times the likelihood of developing psychosis in healthy individuals. It has also been associated with multiple poor prognostic factors in schizophrenia, as well as in patients with a history of psychosis who do not meet diagnostic criteria for schizophrenia. Cannabis has been linked with anxiety; THC has been shown to elicit anxiety; however, anxiety is also a trigger for cannabis use. However, a recent large meta-analysis did not find a convincing link between cannabis and anxiety. This was reiterated in a recent epidemiological study that did not find such a correlation; however, it did identify a link between cannabis use, substance disorder, alcohol use disorder, drug use disorder, and nicotine dependence. Similarly, contradicting data exists regarding the link of depression and cannabis use. Summary: Cannabis use is increasing with recent societal shifts; however, its interaction with mental health is less well understood. CUD is highly prevalent in individuals with mental health disorders, especially those with other substance abuse disorders. There is evidence to support that cannabis use may trigger and worsen psychosis and schizophrenia. The link with depression and anxiety is less clear and needs further investigation. Personality disorder is linked with substance use disorder and shares similar risk factors with CUD.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  alcohol use disorder; anxiety; cannabis use disorder; depression; mental health; personality disorder; substance use disorder

Mesh:

Year:  2020        PMID: 32508368      PMCID: PMC7255842     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  25 in total

1.  Serratus plane block: a novel ultrasound-guided thoracic wall nerve block.

Authors:  R Blanco; T Parras; J G McDonnell; A Prats-Galino
Journal:  Anaesthesia       Date:  2013-08-07       Impact factor: 6.955

Review 2.  Cannabis and mental illness: a review.

Authors:  Darby J E Lowe; Julia D Sasiadek; Alexandria S Coles; Tony P George
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-12-19       Impact factor: 5.270

3.  Long lasting effects of chronic heavy cannabis abuse.

Authors:  Joannis N Nestoros; Elena Vakonaki; Manolis N Tzatzarakis; Athanasios Alegakis; Markos D Skondras; Aristidis M Tsatsakis
Journal:  Am J Addict       Date:  2017-03-17

4.  User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate.

Authors:  Gary C K Chan; Wayne Hall; Tom P Freeman; Jason Ferris; Adrian B Kelly; Adam Winstock
Journal:  Drug Alcohol Depend       Date:  2017-06-08       Impact factor: 4.492

5.  Cannabis exacerbates depressive symptoms in rat model induced by reserpine.

Authors:  Yasser A Khadrawy; Hussein G Sawie; Omar M E Abdel-Salam; Eman N Hosny
Journal:  Behav Brain Res       Date:  2017-02-14       Impact factor: 3.332

Review 6.  Cannabis consumption and psychosis or schizophrenia development.

Authors:  María Bettina Ortiz-Medina; Marta Perea; Julio Torales; Antonio Ventriglio; Giovanna Vitrani; Lourdes Aguilar; Carlos Roncero
Journal:  Int J Soc Psychiatry       Date:  2018-11

Review 7.  Off-label Antidepressant Use for Treatment and Management of Chronic Pain: Evolving Understanding and Comprehensive Review.

Authors:  Ivan Urits; Jacquelin Peck; Mariam Salisu Orhurhu; John Wolf; Riki Patel; Vwaire Orhurhu; Alan D Kaye; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2019-07-29

8.  Cannabis induced psychosis and subsequent psychiatric disorders.

Authors:  Dharav Shah; Prabhat Chand; Mrunal Bandawar; Vivek Benegal; Pratima Murthy
Journal:  Asian J Psychiatr       Date:  2017-10-16

9.  Cannabis use and risk of schizophrenia: a Mendelian randomization study.

Authors:  J Vaucher; B J Keating; A M Lasserre; W Gan; D M Lyall; J Ward; D J Smith; J P Pell; N Sattar; G Paré; M V Holmes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

Review 10.  Current Perspectives on Gut Microbiome Dysbiosis and Depression.

Authors:  Alexander Capuco; Ivan Urits; Jamal Hasoon; Rebecca Chun; Brittany Gerald; Jason K Wang; Hisham Kassem; Anh L Ngo; Alaa Abd-Elsayed; Thomas Simopoulos; Alan D Kaye; Omar Viswanath
Journal:  Adv Ther       Date:  2020-03-04       Impact factor: 3.845

View more
  2 in total

Review 1.  Analyzing the Impact of Cannabinoids on the Treatment of Spinal Disorders.

Authors:  Rohan M Shah; Anjay Saklecha; Alpesh A Patel; Srikanth N Divi
Journal:  Curr Rev Musculoskelet Med       Date:  2022-02-08

Review 2.  Efficacy of Dry Needling and Acupuncture in the Treatment of Neck Pain.

Authors:  Amnon A Berger; Yao Liu; Luke Mosel; Kristin A Champagne; Miriam T Ruoff; Elyse M Cornett; Alan David Kaye; Farnad Imani; Asadollah Shakeri; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Anesth Pain Med       Date:  2021-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.